Nano-X Imaging (NNOX) Q3 2025 earnings summary

Executive summary

• Transitioned from a hardware-focused company to a comprehensive imaging platform, emphasizing global expansion and commercial scale-up, particularly in the U.S. and Europe.

• Strategic focus on technology expansion, AI infrastructure, and operational efficiency for sustainable growth.

• Closed the acquisition of VasoHealthcare IT to expand AI solutions and IT integration, enhancing the U.S. customer base.

• Expanded clinical trials to Cedars-Sinai and Olympe Imagerie, and signed new distribution agreements in the Czech Republic, France, and other European countries.

• Preparing to launch the next-generation, AI-ready ARC X system, targeting broader market penetration.

Financial highlights

• Q3 2025 GAAP net loss was $13.7 million, compared to $13.6 million in Q3 2024.

• Q3 2025 revenue was $3.4 million, up from $3.0 million year-over-year; gross loss was $2.9 million (GAAP).

• Non-GAAP net loss attributable to ordinary shares was $9.9 million, up from $8.7 million in Q3 2024.

• Teleradiology services revenue grew to $3.1 million with a GAAP gross profit margin of 25% and non-GAAP margin of 43%.

• Cash, cash equivalents, and marketable securities totaled $55.5 million as of September 30, 2025.

Outlook and guidance

• Projecting over $35 million in revenue for 2026, with growth ramping up through the year.

• AI business segment expected to reach EBITDA break-even on a quarterly basis in 2026; company-wide EBITDA break-even targeted for 2027.

• Majority of 2026 revenue growth expected from ARC deployments, AI, and new business partners, not teleradiology.

• VasoHealthcare IT acquisition expected to contribute approximately $4 million in annual revenue.

• Expects to have over 100 clinical, demo, and commercial units deployed worldwide by year-end 2025.